Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tufts Medical Center
ClinicalTrials.gov Identifier:
NCT00871624
First received: March 27, 2009
Last updated: February 8, 2013
Last verified: February 2013
  Purpose

The purpose of the study is to determine the efficacy and safety of dexmedetomidine during Non-invasive positive pressure ventilation (NPPV) for patients with acute respiratory failure compared to standard analgesic/sedation practices


Condition Intervention Phase
Acute Respiratory Failure
Drug: Dexmedetomidine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation for Patients With Acute Respiratory Failure: A Randomized, Double-blind, Placebo-controlled Pilot Study

Resource links provided by NLM:


Further study details as provided by Tufts Medical Center:

Primary Outcome Measures:
  • Tolerability of NPPV as assessed by an NPPV tolerance score [ Time Frame: Completed at time 0min, 30min, 60min, 3hr, 6hr, 12hr, and then every 12 hours after the start of NPPV therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent of study time spent with a Riker-SAS score between 3 and 4 inclusive [ Time Frame: Completed at baseline and every 4 hours after the start of NPPV therapy for the duration of the study ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: March 2009
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dexmedetomidine Drug: Dexmedetomidine
Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Other Name: Precedex
Placebo Comparator: Placebo Drug: Placebo
Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Other Name: Precedex

Detailed Description:

Non-invasive positive-pressure ventilation (NPPV) is increasingly being used to manage patients with acute respiratory failure (ARF) in an effort to avoid the numerous negative sequelae associated with intubation and mechanical ventilation. In the USA, it is estimated that 20-30% of all patients placed on mechanical ventilation are treated with NPPV. Indications for NPPV include but are not limited to acute or acute-on-chronic hypercapnic respiratory failure, pulmonary edema, respiratory failure in immunocompromised patients or that due to chest wall deformity or neuromuscular disease. For NPPV to be successful, it is critical that the patient be cooperative and comfortable (i.e. no pain) as agitation and discomfort interfere with the success of NPPV.

Despite the importance of patient comfort during NPPV, physicians infrequently use sedation or analgesic therapy during NPPV, primarily due to concerns about the respiratory depressant effects of most of the sedatives (e.g., benzodiazepines) and analgesics (e.g., opioids) that are currently available. In addition, neither the benzodiazepines nor opioids are easily titratable, can easily accumulate and can be associated with both the development of delirium and a withdrawal effect.

Dexmedetomidine is an intravenous rapid-onset, short acting ά 2-receptor agonist that is approved for short-term sedation in post-operative and critically ill patients. It has been stated that this drug produces a state of "cooperative sedation" allowing the patient to interact with health care providers. Dexmedetomidine has been used for its ability to cause sympatholysis and, because of analgesic properties, to decrease the need for opioids. Potential advantages include its short half life and intravenous route of administration, permitting rapid titration to achieve sedation targets and, in patients with respiratory failure; it can provide both sedation and analgesia without inducing respiratory depression. Despite these advantages, it is currently used by less than 5% of pulmonologists/ intensivists as the primary sedative option during NPPV and has not been studied in a controlled fashion in this population. Therefore, dexmedetomidine may prove to be more efficacious and safe compared to standard sedation/analgesic therapy during NPPV.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Acute respiratory failure requiring the initiation of NPPV
  • Admission to the medical ICU service at Tufts Medical Center or Winchester Hospital

Exclusion Criteria:

  • Patients with delirium (intensive care delirium screening checklist score ≥ 4) or disorientation (not oriented to person or place)
  • Receiving NPPV for ≥ 8 hours (includes treatment with NPPV at an outside hospital)
  • Intubation and mechanical ventilation in the past month based on hospital admission note
  • Age ≥ 85 years
  • Inability of the potential subject to give informed consent
  • Current treatment with antipsychotic agent based on hospital admission note
  • Heart rate ≤ 50 bpm
  • Systolic blood pressure ≤ 90 mmHg
  • History of heart block without pacemaker use or severe ventricular dysfunction (EF ≤25%) based on hospital admission note
  • Acute alcohol withdrawal based on hospital admission note
  • History of end stage liver failure (based on presence of ≥ 1 or more of the following: AST/ALT ≥ 2 times ULN, INR ≥ 2, total bilirubin ≥ 1.5
  • Irreversible brain disease consistent with severe dementia based on hospital admission note
  • Pregnancy (all women of child-bearing age will undergo a pregnancy test prior to study enrollment)
  • Treatment with clonidine or dexmedetomidine in the past 30 days based on hospital admission note
  • Known allergy or sensitivity to clonidine or dexmedetomidine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00871624

Locations
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Winchester Hospital
Winchester, Massachusetts, United States, 01890
Sponsors and Collaborators
Tufts Medical Center
Investigators
Principal Investigator: Nicholas S Hill, MD Tufts Medical Center / Winchester Hospital
  More Information

No publications provided

Responsible Party: Tufts Medical Center
ClinicalTrials.gov Identifier: NCT00871624     History of Changes
Other Study ID Numbers: TuftsMedicalCenter 8533
Study First Received: March 27, 2009
Last Updated: February 8, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Adult
Respiratory Insufficiency
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Dexmedetomidine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014